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INTRODUCTION
Pneumonia is one of the most common diseases
requiring hospitalization. It remains an important
cause of morbidity and mortality despite various ad-
vances in diagnosis, antibacterial therapy, critical
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care, and supportive care, especially in elderly pa-
tients and patients with required hospitalization (1).
Pneumonia was previously classified into commu-
nity-acquired pneumonia (CAP), hospital-acquired
pneumonia (HAP), and ventilator-associated pneu-
monia (VAP). Recently, health-care associated pneu-
monia (HCAP) was defined as a form of HAP or
nosocomial pneumonia by the American Thoracic
Society (ATS) and the Infectious Diseases Society of
America (IDSA) (2). In general, patients with HCAP
are more similar to those with HAP and VAP than
those with CAP, because they have a greater bur-
den of comorbidities, including cancer, chronic kid-
ney disease, heart disease, chronic obstructive pul-
monary disease, dementia, and impaired mobility
(3)-(5). The pathogens that cause HCAP are more
likely to be resistant to multiple antibiotics, as is the
case for HAP and VAP (3) (6). Therefore, it is con-
sidered that the initial treatment of HCAP should
be similar to that of HAP or VAP rather than that
of CAP. Carratala et al . reported that the most com-
mon causative organism for both CAP and HCAP
was Streptoccous pneumonia (7), while Staphylococ-
cus aureus and gram-negative bacilli (except for
Hemophilus species) were less common than in other
reports and no gram-negative bacilli producing ex-
tended-spectrum β - lactamases were found. The
clinical features of HCAP vary among reports. In
Japan, only limited data about HCAP have been pub-
lished so far. In the present study, we investigated
differences of epidemiology, causative organisms,
antibiotic susceptibility, and outcome between pa-
tients with HCAP who were admitted to small hos-
pitals versus large hospitals.
MATERIAL AND METHODS
Patients
A total of 117 patients hospitalized for HCAP were
recruited from December 1, 2009 through April 31,
2010. The study was conducted at eight hospitals
in Japan (Motomachi Hospital, Tottori University
Hospital, Matsue Red Cross Hospital, Matsue Gen-
eral Hospital, San-in Rosai Hospital, Saihaku Hospi-
tal, Chukai Clinic, and Yoka Hospital). Tottori Uni-
versity Hospital, Matsue Red Cross Hospital, Matsue
General Hospital, San-in Rosai Hospital, and Yoka
Hospital each have more than 200 beds, while
Motomachi Hospital, Saihaku Hospital, and Chukai
Clinic each have less than 200 beds. In Japan, hospi-
tals are classified by medical law into three groups :
(1) general hospital which has less than 200 beds,
(2) community supporting hospital which has more
than 200 beds, and (3) advanced treatment hospital.
In this study, a large hospital was defined as 200
beds and a small hospital was 200 beds. In the
large hospitals, only patients who received treatment
from chest physicians were enrolled (large hospital
group). In contrast, all patients hospitalized for
HCAP in the small hospitals were enrolled (small
hospital group), and 13 patients received treatment
from chest physicians.
Evaluation
Diagnosis of pneumonia required the presence
of new radiographic infiltrates plus at least two of
the following : (1) a white blood cell (WBC) count
9,000103/μl or3,000103/μl ; (2) a body tem-
perature38, and (3) purulent secretions from the
lower respiratory tract. Based on the ATS/IDSA
guidelines (2), HCAP was defined as pneumonia
in a patient with at least one of the following risk
factors : (1) hospitalization in an acute care hospital
for two or more days in the last 90 days ; (2) resi-
dence in a nursing home or long-term care facility
in the last 90 days ; (3) receiving outpatient intra-
venous therapy (like antibiotics or chemotherapy)
within the past 30 days ; (4) receiving home wound
care within the past 30 days ; (5) attending a hos-
pital clinic or dialysis center in the last 30 days ;
and (6) having a family member with known multi-
drug resistant pathogens. The outcome measures
evaluated were 30-day survival or discharge from
the hospital within 30 days.
The clinical efficacy of therapy was determined
from improvement of pneumonia based on at least
three of the following : (1) improvement of chest X-
ray findings compare with those at the start of ther-
apy ; (2) a decrease of body temperature to 37;
(3) a decrease of the WBC count to9,000103/μl
and a decrease of C-reactive protein (CRP) to30%
of the pretreatment value (8). The severity of pneu-
monia was graded according to the Japan Respira-
tory Society (JRS) 2005 classification of the severity
of CAP (9), which assesses the age, dehydration,
respiratory failure, disturbance of consciousness,
and low blood pressure (A-DROP score).
Microbiology
Sputum from the respiratory tract was used for
the identification of pathogens according to JRS
guidelines (9). The diagnosis was confirmed by
Gram-staining with phagocytosis and collected heavy
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growth (3+ ; adapted from 1105 cfu/ml to 1107
cfu/ml of sample). Single or paired sera were used
to detect antibodies against Mycloplasma pneumoniae
and Chlamydia pneumoniae. Legionella pneumophilia
serogroup I antigen was detected in urine samples
by immunochromatography (NOW Legionella Uri-
nary Antigen Test ; Binax Inc., United States).
Data analysis
Results are shown as the meanstandard error
(SE). SPSS software (Japanese version 16.0 for Win-
dows ; SPSS Japan Inc., Tokyo, Japan) was used for
statistical analysis. Comparisons between groups
were done with the Mann-Whitney nonparametric
test, while the χ2 test was employed for categorical
data. Significance was defined as p0.05 for all
analyses.
RESULTS
Patient characteristics
During the study period, 117 adults with HCAP
were hospitalized, with 61 patients being admitted
to large hospitals (200 beds) and 56 patients be-
ing admitted to small hospitals (200 beds). The
characteristics of patients from the large hospital
group and the small hospital group are compared
in Table 1. The large hospital group had more male
patients than the small hospital group. Among the
HCAP criteria, outpatient intravenous therapy had
been received by 21.3% in the large hospital group
versus 5.4% in the small hospital group, while the
frequency of attending a hospital clinic or dialysis
center was 39.3% in the large hospital group versus
7.1% in the small hospital group, and there were
significant differences between the two groups (P
0.05). However, there was a significant difference
in the prevalence of chronic heart disease (P0.05).
In addition, respiratory failure and impaired con-
sciousness were more frequent in the large hospi-
tal group compared with the small hospital group
(P0.05). As a result, the large hospital group had
more severe disease than the small hospital group
(P0.05) according to the A-DROP classification.
There was also a significant difference in the use
of antibiotic therapy before hospitalization by two
groups (P0.05).
Causative pathogens
The causative pathogens in the large hospital
group and the small hospital group are shown in
Table 2. The percentage of patients with a confirmed
etiologic diagnosis was not significantly different
Table 1 Main Clinical Characteristics of Patients by Epidemiological Group
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between the two groups (31.4% in the large hospital
group versus 32.1% in the small hospital group).
Gram-positive pathogens were more frequently iso-
lated in the small hospital group than in the large
hospital group. In the small hospital group, gram-
positive pathogens were more frequent than gram-
negative pathogens. In contrast, there was no sig-
nificant difference in the frequency of pathogens in
the large hospital group. Atypical pathogens were
not detected in either group.
Antibiotic therapy and clinical outcome
Table 3 shows the antibiotic therapy provided and
the outcome. More than 94% of the patients received
β - lactam monotherapy in both the small hospital
group and the large hospital group. There were no
differences of initial antibiotic therapy between the
large and small hospital groups. The rate of initial
treatment failure was 13.1% in the large hospital
group versus 17.9% in the small hospital group, with
no significant difference between the two groups.
A similar percentage of patients in both groups had
a relapse after apparently successful treatment.
There was also no difference between the two
groups with regard to the duration of therapy.
The overall death rate was 8.2% in the large hos-
pital group and 1.8% in the small hospital group. In
the large hospital group, one patient died within 48
hours of hospitalization due to respiratory failure.
The early and overall death rates were not signifi-
cantly different between the two groups. Table 4
shows the details of the fatal cases. Five out of 6
patients who died were in the very severe A-DROP
class and one patient was severe. Overall, 12 pa-
tients belonged to the very severe class in the large
hospital group versus 3 patients in the small hospital
group (Table 1). The mortality rate of patients from
the very severe A-DROP class was 33.3% in both
groups (4/12 patients in the large hospital group
versus 1/3 patients in the small hospital group). In
contrast, no patient died in either group when the
A-DROP class was moderate or mild. All of the pa-
tients who died had comorbidities, including chronic
heart failure in 2 patients, cerebrovascular disease
in 2 patients, COPD in 1 patient, and autoimmune
disease in 1 patient. In addition, all of them received
β - lactam monotherapy. In 5 out of 6 patients, a
causative pathogen was not identified.
Table 2 Etiology in 117 Cases of Pneumonia by Epidemiological Group
M. Watanabe, et al. Difference of health-care associated pneumonia according to hospital scale70
DISCUSSION
This study showed that90% of the patients hos-
pitalized with HCAP survived and that the A-DROP
severity class closely reflected the risk of mortality
in both the small hospital group (200 beds) and
the large hospital group (200 beds). Approximately
33% of the patients in the very severe A-DROP class
died within 30 days of hospital admission in both
groups and 10% of patients failed to respond to
initial antibiotic therapy in both groups. Compared
with the small hospital group, the large hospital
group had a higher percentage of patients with res-
piratory failure and disturbance of consciousness,
more male patients, and more high-risk patients.
There was also a significant difference in the fre-
quency of antibiotic therapy before hospitalization
and the HCAP criteria between the two groups.
In recent years, the increase of patients who are
elderly and severely disabled has led to the intro-
duction of a new category of pneumonia known as
health-care associated pneumonia (HCAP) (10).
However, there is limited information to validate
HCAP and a substantial number of HCAP patients
Table 3 Antibiotic Therapy and Outcomes of Pneumonia by Epidemiological Group
Table 4 Characteristics in Fatality Cases
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can be defined as having community-associated
pneumonia (CAP) (2, 6). Various changes to the
health system have shifted a considerable part of
patient care from the hospitals to the community. In
addition, there are marked differences of medical
management and the health care system between
countries. As a result, the epidemiology and out-
come of HCAP have not necessarily shown agree-
ment in various studies (6, 11-14). In this study,
we evaluated differences in the epidemiology and
outcome of HCAP between large and small hospitals
in Japan.
In this study, we found that the large hospital
group had more patients with severe and very se-
vere pneumonia than the small hospital group.
There are two possible reasons for this result. One
is that the type of hospital was selected by the fam-
ily or the staff of the residential facility based on the
condition of the patient, and the other is the higher
percentage of patients receiving antibiotics before
hospitalization in the large hospital group. Patients
were also more likely to have respiratory failure or
disturbance of consciousness in the large hospital
group compared with the small hospital group, sug-
gesting that family members or staff took the pa-
tients to larger hospitals when their condition was
more severe since large hospitals have better facili-
ties and emergency units. In contrast, the family or
staff would be more likely to take the patients to
smaller hospitals when their condition was mild. It
should be noted that hospitals can be selected freely
by the patient or family under the Japanese national
health system. Some patients received antibiotic
therapy at home or in their residential care facility
and they might be preferentially taken to large hos-
pitals rather than small hospitals when the initial
antibiotic treatment failed. The reported mortality
rate of HCAP varies among studies (6, 11-14), sug-
gesting that there are considerable differences in
the severity of patients with HCAP presenting to
different institutions.
In this study, we did not find a difference of mor-
tality between the large hospital group and the small
hospital group, possibly because the number of pa-
tients in this investigation was small. We did find
that patients with severe HCAP tended to be admit-
ted to large hospitals more often than small hospi-
tals and that patients with very severe pneumonia
had a high mortality rate in both groups. Therefore,
a significant difference of the mortality rate may
have been detected between the large hospital
group and the small hospital group if the number
of patients was increased.
A severity classification for HCAP has not been
established yet. In this study, the A-DROP severity
class corresponded to the mortality rate in both the
small hospital group and the large hospital group.
Among 6 patients who died, five were classified as
very severe and one patient was in the severe class.
However, it is likely that there would be lower cor-
respondence with a pneumonia risk classification
like CURB-65 or the pneumonia severity index (14-
17). This is because the risk factor of drug-resistant
pathogens (DRPs) is not reflected in the pneumonia
severity classification. We considered that a possi-
ble reason for the correspondence of the A-DROP
severity class with mortality was the low rate of
DRPs in this series. On the other hand, El Solh et
al . reported the effectiveness of a classification tree
with ADL for predicting the risk of DRPs in patients
with nursing home-acquired pneumonia (16). It
may be necessary to establish a severity classifica-
tion for HCAP based on ADL instead of age, be-
cause our patients with HCAP were much older
than patients with CAP.
In this series, the 6 patients who died were all in
the very severe (n=5) or severe (n=1) A-DROP
class and all of them received β - lactam monother-
apy. In contrast, most of the patients in our series
responded to β - lactam monotherapy. Brito et al .
reported that HCAP was a heterogeneous disease,
so all patients did not need the same broad-spec-
trum antibiotic therapy as that given for complex
nosocomial pneumonia (14). It has been empha-
sized in the literature that early initiation of appro-
priate and adequate antibiotic therapy is important
for improving the outcome of patients with HCAP
(18-20). Although recommended therapy for HCAP
based on an existing pneumonia severity classifica-
tion has not been established, it seems important
to treat patients with a β - lactam plus a macrolide or
quinolone or with three antibiotics if their A-DROP
class is severe or very severe irrespective of the
size of the hospital to which they are admitted.
In this study, the mortality rate was 8.2% in the
large hospital group versus only 1.8% in the small
hospital group. The mortality rate in both groups
was low compared with the rates in other studies of
HCAP (11-12). Labelle et al . reported that patients
with culture-negative HCAP had less severe illness,
a lower hospital mortality, and a shorter length of
hospital stay compared with culture-positive patients
(21). Venditti et al . reported that establishing a mi-
crobiological diagnosis of pneumonia was associated
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with a higher in-hospital death rate by univariate
analysis, but not multivariate analysis, in patients
with CAP and HCAP. Some studies of CAP have
suggested that establishing an etiologic diagnosis
may not significantly influence the outcome, includ-
ing the length of hospital stay or mortality (22, 23).
The frequency of identified causative pathogens in
this study was 31.6%, which was lower than in the
other studies (6-7, 11-12), so the low mortality in
this study may be associated with the fact that a
causative organism was not identified in 68.4% of the
patients. Thus, the frequency of aspiration pneumo-
nia might have been high in both groups in the
present study.
Other studies documented that potentially drug-
resistant (PDR) pathogens occurred frequently
among HCAP (1, 3, 6). However, in this study, the
frequency of identified PDR pathogens was 4 out of
117 patients, and lower than other studies. Patho-
gens in 5/6 patients of fatality cases were not iden-
tified. It might be that PDR pathogens were causa-
tive organism in five fatality cases. Our study had
certain limitations that should be acknowledged,
because a number of patients were relatively small.
Therefore, our result should be interpreted with
caution.
In conclusion, our findings suggested that the
characteristics of patients with HCAP are different
between those admitted to large hospitals or small
hospitals, especially with regard to the severity of
pneumonia. Patients in the very severe A-DROP
class have a much higher mortality rate compared
with those in other classes and such patients require
intensive antibiotic therapy. On the other hand, not
all patients with HCAP need the broad-spectrum an-
tibiotics. Further studies of a larger number of pa-
tients from hospitals of different sizes are needed
confirm our findings.
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